The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

case-study
From CDMO to In-House cGMP Manufacturing: Scaling Success in Cell Therapy Technology Transfer
Read More

post
The U.S.-China Trade War and Its Impacts on Investigational Drug Supply Chains
Read More

poster
International Technology Transfers: A Playbook for Success
Read More

post
FDA Approval Process for Vaccines
Read More
Let's move from science to success.
Let’s Talk